Ispire Technology Inc. — Form 10-Q Summary
Business context and period. This is Ispire Technology Inc.’s unaudited quarterly report for the three and six months ended December 31, 2023, the second quarter and first half of fiscal 2024. The company sells tobacco vaping products internationally and cannabis vaping hardware primarily in the United States.
Financial performance
| Metric | Three months ended Dec. 31, 2023 | Year-over-year change | Six months ended Dec. 31, 2023 | Year-over-year change |
|---|---|---|---|---|
| Revenue | $41.69 million | Up 30.7% | $84.55 million | Up 43.7% |
| Gross profit / margin | $6.38 million / 15.3% | Margin down from 16.1% | $13.26 million / 15.7% | Margin down from 16.9% |
| Operating income (loss) | $(3.95) million | Prior period: $0.31 million income | $(4.86) million | Prior period: $(0.91) million |
| Net income (loss) | $(4.02) million | Prior period: $(0.13) million | $(5.40) million | Prior period: $(2.13) million |
| Operating cash flow | Not separately provided for the quarter | $(20.23) million | Prior period: $8.38 million |
Quarterly revenue growth was driven by cannabis vaping sales, which rose to $19.55 million from $7.84 million; tobacco vaping sales declined to $22.13 million from $24.06 million. For the six-month period, tobacco sales were $47.67 million and cannabis sales were $36.88 million. Management attributed lower cannabis margins to price concessions for larger customers and a mix shift toward lower-margin products. Six-month operating costs also included $2.85 million of stock-based compensation and $2.13 million of credit-loss expense.
Financial position and liquidity
- Cash was $17.50 million at December 31, 2023, down from $40.30 million at June 30, 2023. Current assets were $83.01 million and current liabilities were $58.52 million; reported working capital was approximately $24.78 million.
- Net accounts receivable increased to $45.45 million from $24.53 million. The credit-loss allowance rose to $2.92 million from $1.50 million; the company recorded $2.13 million of credit-loss expense for the six months.
- Current liabilities included $49.00 million payable to related-party supplier Shenzhen Yi Jia. The filing states these balances have no fixed payment terms and are classified as current. Total operating lease liabilities were $4.31 million.
- Six-month investing cash use was $1.86 million, mainly property and equipment purchases and patent costs. Financing cash use was $0.70 million, primarily repayment of related-party advances. No conventional interest-bearing borrowing balance is identified in the supplied filing text.
- Management said cash and working capital should meet needs for the next 12 months, while cautioning that adverse conditions, unexpected spending, or accelerated growth could require additional financing.
Material changes, outlook and risks
- Operating cash flow swung to a $20.23 million use, primarily reflecting a $22.76 million increase in accounts receivable. Cash declined by $22.80 million over the six months.
- The company depends heavily on related-party manufacturing: Shenzhen Yi Jia, 95% owned by the co-CEO, supplied 70% of purchases for the six months. One customer represented 30% of six-month revenue; two customers together accounted for 25% of year-end receivables.
- Management provided no specific revenue, earnings, or margin guidance. It cited regulatory uncertainty, competition, customer collections, and potential manufacturing or supply disruption as business risks. U.S. cannabis sales face state-by-state rules and federal-law risk; the FDA could reject the company’s pending PMTA for one tobacco vaping product. The company has stopped marketing tobacco vaping products in the United States.
- Financial statements were restated for the December 2022 comparative period after the company concluded that transferred intellectual property should have been recorded at the related party’s nil book value, rather than an independent valuation. The restatement reduced prior-period losses. Lease cash-flow classification was also corrected.
- Management concluded disclosure controls and procedures were not effective, citing weaknesses in controls for related-party asset transactions, estimates including inventory and credit-loss reserves, and written control policies. Remediation efforts were underway.
- Subsequent to quarter-end, the company disclosed a term sheet for a proposed 50/50 joint venture with Berify, with Ispire intending to contribute up to $10 million for research and development, PMTA submissions, and software development. Definitive documents and final terms were not reported as completed.
- A December 2023 BRKFST licensing agreement provides for royalties based on an agreed percentage of net profits and joint marketing; there were no sales under the license in the reported quarter or six-month period.
Important facts for investors to verify
- Whether the sharp increase in receivables is collected on schedule and whether credit-loss reserves adequately reflect customer risk.
- Payment arrangements and ongoing dependence on Shenzhen Yi Jia, including the related-party payable balance and supplier concentration.
- Whether margins stabilize as cannabis sales grow, given the reported lower pricing and product-mix effects.
- Progress in remediating material weaknesses and whether subsequent filings report effective controls.
- FDA status of the pending PMTA, developments in U.S. cannabis regulation, and the final terms and funding obligations of the proposed Berify joint venture.